ProSomnus (NASDAQ:OSA – Get Free Report)‘s stock had its “hold” rating reaffirmed by research analysts at Craig Hallum in a note issued to investors on Friday, Benzinga reports. They currently have a $1.00 price objective on the stock. Craig Hallum’s price objective would indicate a potential upside of 143.90% from the company’s current price. Separately, […]
ProSomnus (NASDAQ:OSA – Free Report) had its price objective decreased by Roth Mkm from $6.00 to $4.00 in a research note released on Tuesday morning, Benzinga reports. Roth Mkm currently has a buy rating on the stock. ProSomnus Price Performance Shares of ProSomnus stock opened at $1.10 on Tuesday. ProSomnus has a 12-month low of […]
ProSomnus (NASDAQ:OSA – Get Free Report) and TransMedics Group (NASDAQ:TMDX – Get Free Report) are both medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their risk, institutional ownership, dividends, profitability, analyst recommendations, earnings and valuation. Analyst Recommendations This is a breakdown of current ratings […]
ProSomnus (NASDAQ:OSA – Get Rating) and iCAD (NASDAQ:ICAD – Get Rating) are both small-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their dividends, institutional ownership, earnings, analyst recommendations, valuation, profitability and risk. Valuation & Earnings This table compares ProSomnus and iCAD’s revenue, earnings […]